Terms ending in 2035
Every in-force patent on GlaxoSmithKline LLC's record whose computed term ends in 2035, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,486,941 | Phenyl Amino Pyrimidine Compounds and Uses Thereof In force · High confidence | GlaxoSmithKline LLC | In force | High confidence | |
| US 9,809,559 | (N-(CYANOMETHYL)-4-(2-(4-Morpholinophenylamino)PYRIMIDIN-4-YL)BENZAMIDE In force · Medium confidence | GlaxoSmithKline LLC | In force | Medium confidence | |
| US RE48,285 | N-(Cyanomethyl)-4-(2-(4-Morpholinophenylamino)Pyrimidin-4-YL) Benzamide In force · Low confidence | GlaxoSmithKline LLC | In force | Low confidence | |
| US RE49,445 | N-(Cyanomethyl)-4-(2-(4-Morpholinophenylamino)Pyrimidin-4-YL) Benzamide In force · Low confidence | GlaxoSmithKline LLC | In force | Low confidence | |
| US RE50,497 | (N-(Cyanomethyl)-4-(2-(4-Morpholinophenylamino)Pyrimidin-4-y l)Benzamide In force · Low confidence | GlaxoSmithKline LLC | In force | Low confidence | |
| US 10,653,693 | PRMT5 Inhibitors and Uses Thereof In force · High confidence | GlaxoSmithKline Intellectual Property Development Limited | In force | High confidence |
6 of 6 patents shown. Soonest term end first, then patent number.
5 of these are in force and held by GlaxoSmithKline LLC.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.